To clinically apply the inverse PSA-body mass index (BMI) correlation and enhance PSA sensitivity in obese cases, a new formula is warranted. ). Cases stratified based on their age (every 10 years). The new equation was applied. Obesity is detected in 33.5 and 43.6% of fifth and sixth decade of life respectively (P ¼ 0.02), with low measured PSA values (2.1, 3.8 ng ml À1 , respectively). By such PSA measurement biopsy may be omitted, missing 53.3% of malignant cases. In contrast, PSA adjusted were 4 and 9.3 ng ml À1 within the same group of patients. With such values, the decision of a biopsy could not be missed for the targeted groups. Specificity and sensitivity of adjusted PSA values at cutoff point 4 ng ml À1 was 41.7 and 70%, respectively. Based on our results, the new PSA-BMI adjusted formula is reproducible, easy applied formula. With such a formula the higher sensitivity of PSA in obese patients could be achieved. The misleading low PSA in obese cases in the fifth and sixth decade will be corrected.
Introduction
Till date, many reports have been discussed on the inverse relationship between PSA and body mass index (BMI) in prostate cancer patients. Investigators have shown that PSA levels are lower in obese men. [1] [2] [3] Moreover, obesity is a significant risk factor for prostate cancer at the time of biopsy. 4 However, how could this inverse correlation be employed in the clinical practice; what are the benefits of this correlation in obese cases; and can we omit unnecessary biopsy or avoid missing cases of prostate cancer. All these questions and more have not been answered till date. Also, the impact of age on this correlation is poorly defined in the literature.
Our hypothesis is to define whether an equation could be applied clinically regarding this correlation. Therefore, a newly PSA-BMI adjusted value is introduced, by which an increase in PSA specificity and sensitivity in obese cases could be achieved.
We aimed to define an equation between PSA, BMI and age. With such an equation we can create a new adjusted PSA-BMI value, which can be used to increase the sensitivity of PSA measurement for all cases, notably the obese ones.
Materials and methods
A newly designed formula has been suggested, which is aimed at creating an established clinically applied equation to all the cases through which the BMI, measured total PSA and their relation are used.
All the cases were provided signed and informed consent. The study was approved by our Institutional Review Board.
PSA-BMI-age adjusted formula is defined as: measured total serum PSA (ng ml
À1
) multiplied by age (year) and divided by BMI of the patient, Appendix A.
The yield is the adjusted PSA-BMI value.
To test this equation on population, analysis of randomly selected 1000 patients who underwent transrectal ultrasound and biopsy, from January 2006 to January 2008, were included in this study. Trans-rectal ultrasound prostatic biopsies was done whenever PSA44 ng ml À1 and/or abnormal digital rectal examination, and histopathology were retrieved.
For all cases, age, total serum PSA, total and transitional prostatic volume, patient's weight, height and subsequent BMI were retrieved. Analysis of corresponding data based on age stratification (every 10 years, based on Oesterling et al., 5 PSA stratification (o and X4 ng ml À1 ), BMI (obese or not) and pathology (benign or not) was carried out.
Obesity is commonly assessed by using BMI, the most widely used metric for identifying obesity is having a BMI greater than 30. BMI is defined as the weight in kilograms divided by the square of the height in meters (kg m À2 ), Appendix B. According to WHO, obesity classified according to BMI is as fellow; normal range 18.5-24.9, overweight 425.0, pre-obesity 25.0-29.9, obesity class I 30.00-34.9, obesity class II 35.00-39.9 and obesity class III 440.0. The data was processed using SPSS 11.0 for Windows (SPSS, Chicago, IL, USA). Statistical analysis of continuous variable means and medians was carried out using Student t-tests (paired and unpaired, when appropriate). Analysis of non-continuous variables was carried out using w 2 test, one way analysis of variance test. A P value ofo0.05 was considered statistically significant. Receiver operating characteristics curve was used to define the specificity and sensitivity of the tested equation.
The statistical power of the study was calculated using G*power program (University of Dü sseldorf, Dü sseldorf, Germany) using post-hoc mode calculation and an effect size conversion of 0.5 for the two-tailed t-test, with a error protection of 0.05, provided 92% power of sample size of patients in each group.
Results
The new equation was tested among randomly selected 1000 cases of different age, BMI groups who underwent biopsies for different prostatic indications. Valid complete data were achieved for 988 cases. Table 1 shows the stratification of cases according to age (stratified by each 10 years) and BMI. Majority of obese cases (BMI430 kg m À2 ) are over 50 years, 33.5 and 43.6% were in fifth and sixth decade of life, respectively (P ¼ 0.02). Table 2 shows a correlation between the pathology yield by TRUS biopsy (as a corner stone for prostate cancer detection), measured PSA, adjusted PSA, BMI, total volume of the gland and total volume prostatic density.
Among the detected malignant cases, eight cases (53.3%) were in the fifth and sixth decade of life (P ¼ 0.0001). It is interesting to note that these two age groups have particularly low measured PSA values that could be missed, an absolute indication of biopsy.
Moreover, the adjusted PSA-BMI is relatively higher than the measured PSA values and with the new equation the indication of biopsy is mandatory.
Oesterling et al. 5 established age-PSA stratification and proved its applicability. The age reference was used in Table 2 to compare the measured values and adjusted PSA values against standard age range of Oesterling et al. 5 The biopsy decision will not be neglected with PSA-BMI adjusted value when compared with PSA-age range of Oesterling et al., 5 in contrast to the actual measured PSA.
In the cohort of patients, specificity and sensitivity of new adjusted PSA values in benign cases at cutoff point 4 ng ml À1 was 41.7 and 70%, respectively, Figure 1 . Although specificity and sensitivity of the new adjusted PSA values in non-benign cases at cutoff point 4 ng ml À1 was 29.3 and 58.3%, respectively, Figure 2 .
With this equation we could detect 53.3% of malignant cases among our cohort, who could be missed had we used ordinary measured PSA among obese males at fifth and sixth decade.
It is interesting to note that the sensitivity for detection had jumped to 82.5% when a cutoff point 2.5 ng ml À1 was used with specificity 30.6%.
Discussion
The PSA test is commonly used as a screening tool, as a part of the diagnostic workup to rule out prostate cancer as well as the management. 7 Many cases undergo a needle prostatic biopsy prompted by high-serum PSA concentration, aiming for early prostate cancer detection Obesity-PSA relationship IA Hekal and EI Ibrahiem that will be associated with high curative rate and subsequent good prognosis and long survival rate.
The inverse correlation of PSA and BMI has been established by many authors. [1] [2] [3] Some have proposed this as a mechanism for later detection of prostate cancer in obese men. 8, 9 As PSA is regulated by androgen, investigators have hypothesized that lower PSA concentration may result from decreased androgenic activity in obese men. 9, 10 However, men with higher BMI also have larger plasma volumes, which could decrease serum concentration of soluble tumor markers-a phenomenon known as hemodilution. 11 This explanation was validated by Branz and co-workers study on prostate cancer patients. [12] [13] [14] The main aim of this study was to find a useful clinically applied equation based on the already established PSA-BMI correlation, as well as to test our hypothesis based on this equation, we applied this equation in randomly selected previously biopsied cases, comparing our data with Oesterling et al. 5 We are not referring to the use of any of TRUS data (that is, volume and density). This is based on two reasons; first is the subjective error that could be countered during measurements; and second is our aim itself, which is supplying an equation before any invasive maneuver (TRUS). Based on those objectives data (age, PSA and BMI all are fixed items with minimal human error and without any subjective bias), we can judge either to carry out TRUS and biopsy or not.
To the best of our knowledge, no previous equation has been tried on BMI-PSA correlation in English literature. 
Obesity-PSA relationship IA Hekal and EI Ibrahiem
Ever since the introduction of PSA, many authors and investigators have tried to increase its specificity (to prepare a serum PSA, a more discriminating for detecting clinically significant cancers) and sensitivity (to find more potentially curable cancers).
Although Kim et al. 15 found that the correlation between PSA and BMI, based on 60 years age stratification, was significant inverse relation in younger patients only and not with the older patients. On other hand, in another study, coincidence finding between PSA and BMI was observed as direct relation in patients o50 years of age, whereas PSA is o4 ng ml À1 . 16 To alleviate this point, we addressed the standard ageadjusted PSA by Oesterling et al.
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Although among our cases, obese men had a relatively larger prostate (mean ± s.d. ¼ 64.3 ± 4.6 gms) versus nonobese (mean ± s.d. ¼ 56.3 ± 3.2 gms) P ¼ 0.153, a normal PSA density is achieved. This could be attributed to obese patients (BMI430 kg m
À2
), who have a PSA o4 ng ml À1 in 31.9%, whereas those who have a higher PSA are 33.5% (P ¼ 0.657). This cope with other data that obese patients are associated with large prostatic volumes. 17, 18 Among our results, the majority of the fifth and sixth decades are obese, BMI430 kg m À2 (who are the targeted group for screening and may gain benefits from early detection and surgery for curability).
As 38.8% (108 cases) were obese among fifth decade with median PSA, 2.1 ng ml À1 (range: 0.13-105 ng ml
À1
), which when compared with PSA-age adjusted range is considered low and the biopsy could be omitted, with subsequently missing 20% of the diagnosed malignant cases among our cohort. On the other hand the median of adjusted PSA by our formula raised the PSA to 4 ng ml À1 which is higher than the PSA-age adjusted range by Oesterling et al. 5 and the biopsy should not be postponed. The same was applied within the sixth decade, the obese cases were 32.6% (135 cases). Median measured PSA was 3.8 ng ml À1 , which is lower than the ageadjusted PSA. 5 Although the BMI-PSA adjusted measure was 9.3 ng ml
, 33.3% of malignant cases should not be missed among this age group.
By this equation, biopsy decision could not be missed for the obese cases, with low measured PSA as we have a sensitivity reach of 70% with the adjusted BMI-PSA; 4 ng ml À1 among the entire cohort of patients irrespective of age stratification which jumped to 82% with the adjusted BMI-PSA cutoff point 2.5 ng ml À1 . For example, an adult man aged 55 years with BMI 30 kg m À2 the PSA was 3 ng ml
. The PSA-BMI adjusted value (Appendix A) will be (3 Â 55/30 ¼ 5.5 ng ml À1 ). In this example, this obese man at first look, will lose the chance for TRUS-biopsy (PSA o4 ng ml À1 ) and subsequently may lose the chance for active treatment if prostatic adenocarcinoma was encountered. Although when we apply Hekal's equation, an adjusted PSA value was 5.5 ng ml
, which is higher than ordinary accepted cutoff point (4 ng ml À1 ) as well as the age-adjusted PSA (3.5 ng ml À1 ), 5 so the biopsy should not be postponed. The main limitation of our study is the number of malignant cases. This is indeed the condition of our locality, which has a low incidence of prostate cancer rather than other urological malignancy.
Finally, a recommendation of worldwide testing of this hypothesis and equation is mandatory before standardization.
Conclusions
Based on our results, we supposed that the use of BMI-PSA equation could achieve high sensitivity in screening and alleviate the misleading low measured PSA for early biopsy detection of prostate cancer in all the cases, notably for those who are obese and who are candidates for curable treatment (fifth and sixth decade).
